Clinical Trial Update: Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) [Phase 2]

View source ↗

Summary

A phase 2 clinical trial (CORAL) is evaluating loncastuximab tesirine plus rituximab as a bridging therapy before standard CAR-T therapy in relapsed or refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Large B-cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: University of Utah | Conditions: Relapsed or Refractory Large B-cell Lymphoma | Phase 2 | Status: RECRUITING